Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody

Virology

Volumn 411, Issue 1, 2011, Pages 132-141

  Walsh, Renae ^a   Nuttall, Stewart ^b   Revill, Peter ^a   Colledge, Danni ^a   Cabuang, Liza ^a   Soppe, Sally ^a   Dolezal, Olan ^b   Griffiths, Kate ^b   Bartholomeusz, Angeline ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b CSIRO   (Australia)

Author keywords

Bacteriophage display; BIAcore kinetics; Chronic hepatitis B; Endoplasmic reticulum; Hepatitis B e antigen; Intrabody; New antigen receptor; Precore

Indexed keywords

EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN NEW ANTIGEN RECEPTOR; PROTEIN P17; PROTEIN P21; PROTEIN P25; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS REACTION; DRUG DETERMINATION; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; INTRACELLULAR SPACE; MOLECULAR CLONING; MOLECULAR LIBRARY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION;

BIOLOGICAL PRODUCTS; CELL LINE; ENDOPLASMIC RETICULUM; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN TRANSPORT; SEQUENCE ANALYSIS, DNA; SINGLE-CHAIN ANTIBODIES;

CHONDRICHTHYES; HEPATITIS B VIRUS;

EID: 79551685528     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.12.034     Document Type: Article

References (52)

1. Bai J., Sui J., Zhu R.Y., Tallarico A.S., Gennari F., Zhang D., Marasco W.A. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 2003, 278(3):1433-1442.
2. Cardinale A., Filesi I., Vetrugno V., Pocchiari M., Sy M.S., Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J. Biol. Chem. 2005, 280(1):685-694.
3. Chang C., Enders G., Sprengel R., Peters N., Varmus H.E., Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J. Virol. 1987, 61(10):3322-3325.
4. Chen R.Y., Edwards R., Shaw T., Colledge D., Delaney W.E.T., Isom H., Bowden S., Desmond P., Locarnini S.A. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003, 37(1):27-35.
5. Chen M.T., Billaud J.N., Sallberg M., Guidotti L.G., Chisari F.V., Jones J., Hughes J., Milich D.R. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl Acad. Sci. USA 2004, 101(41):14913-14918.
6. Chen M., Sallberg M., Hughes J., Jones J., Guidotti L.G., Chisari F.V., Billaud J.N., Milich D.R. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 2005, 79(5):3016-3027.
7. Chen C.Y., Crowther C., Kew M.C., Kramvis A. A valine to phenylalanine mutation in the precore region of hepatitis B virus causes intracellular retention and impaired secretion of HBe-antigen. Hepatol. Res. 2008, 38(6):580-592.
8. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R., et al. Conformations of immunoglobulin hypervariable regions. Nature 1989, 342(6252):877-883.
9. Coia G., Ayres A., Lilley G.G., Hudson P.J., Irving R.A. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene 1997, 201(1-2):203-209.
10. Delaney W.E.T., Isom H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998, 28(4):1134-1146.
11. Dienes H.P., Gerken G., Goergen B., Heermann K., Gerlich W., Meyer zum Buschenfelde K.H. Analysis of the precore DNA sequence and detection of precore antigen in liver specimens from patients with anti-hepatitis B e-positive chronic hepatitis. Hepatology 1995, 21(1):1-7.
12. Dooley H., Flajnik M.F. Antibody repertoire development in cartilaginous fish. Dev. Comp. Immunol. 2006, 30(1-2):43-56.
13. Dooley H., Stanfield R.L., Brady R.A., Flajnik M.F. First molecular and biochemical analysis of in vivo affinity maturation in an ectothermic vertebrate. Proc. Natl Acad. Sci. USA 2006, 103(6):1846-1851.
14. Fried M.W., Piratvisuth T., Lau G.K., Marcellin P., Chow W.C., Cooksley G., Luo K.X., Paik S.W., Liaw Y.F., Button P., Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47(2):428-434.
15. Galanis M., Irving R.A., Hudson P.J. Bacteriophage library construction and selection of recombinant antibodies. Current protocols in Immunology 1997, 17.1.1-17.1.45. John Wiley and Sons, NY.
16. Greenberg A.S., Avila D., Hughes M., Hughes A., McKinney E.C., Flajnik M.F. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995, 374(6518):168-173.
17. Ito K., Kim K.H., Lok A.S., Tong S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J. Virol. 2009, 83(8):3507-3517.
18. Johnsson B., Lofas S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 1991, 198(2):268-277.
19. Kane M.A. Global status of hepatitis B immunisation. Lancet 1996, 348(9029):696.
20. Kopsidas G., Roberts A.S., Coia G., Streltsov V.A., Nuttall S.D. In vitro improvement of a shark IgNAR antibody by Qbeta replicase mutation and ribosome display mimics in vivo affinity maturation. Immunol. Lett. 2006, 107(2):163-168.
21. Ladner S.K., Otto M.J., Barker C.S., Zaifert K., Wang G.H., Guo J.T., Seeger C., King R.W. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 1997, 41(8):1715-1720.
22. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11(2):97-107.
23. Locarnini S., Shaw T., Dean J., Colledge D., Thompson A., Li K., Lemon S.M., Lau G.G., Beard M.R. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J. Clin. Virol. 2005, 32(2):113-121.
24. Lynch S.M., Zhou C., Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 2008, 377(1):136-147.
25. Messageot F., Salhi S., Eon P., Rossignol J.M. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J. Biol. Chem. 2003, 278(2):891-895.
26. Milich D.R., Jones J.E., Hughes J.L., Price J., Raney A.K., McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proc. Natl Acad. Sci. USA 1990, 87(17):6599-6603.
27. Milich D.R., Chen M.K., Hughes J.L., Jones J.E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 1998, 160(4):2013-2021.
28. Minsky A., Summers R.G., Knowles J.R. Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc. Natl Acad. Sci. USA 1986, 83(12):4180-4184.
29. Muyldermans S., Lauwereys M. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J. Mol. Recognit. 1999, 12(2):131-140.
30. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42(9):3858-3863.
31. Nuttall S.D., Walsh R.B. Display scaffolds: protein engineering for novel therapeutics. Curr. Opin. Pharmacol. 2008, 8(5):609-615.
32. Nuttall S.D., Krishnan U.V., Hattarki M., De Gori R., Irving R.A., Hudson P.J. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001, 38(4):313-326.
33. Nuttall S.D., Krishnan U.V., Doughty L., Pearson K., Ryan M.T., Hoogenraad N.J., Hattarki M., Carmichael J.A., Irving R.A., Hudson P.J. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur. J. Biochem. 2003, 270(17):3543-3554.
34. Nuttall S.D., Humberstone K.S., Krishnan U.V., Carmichael J.A., Doughty L., Hattarki M., Coley A.M., Casey J.L., Anders R.F., Foley M., Irving R.A., Hudson P.J. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004, 55(1):187-197.
35. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 1994, 31(3):169-217.
36. Reiter Y., Brinkmann U., Lee B., Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat. Biotechnol. 1996, 14(10):1239-1245.
37. Revill P., Yuen L., Walsh R., Perrault M., Locarnini S., Kramvis A. Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J. Med. Virol. 2010, 82:104-115.
38. Riordan S.M., Skinner N., Kurtovic J., Locarnini S., Visvanathan K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin. Vaccine Immunol. 2006, 13(8):972-974.
39. Roux K.H., Greenberg A.S., Greene L., Strelets L., Avila D., McKinney E.C., Flajnik M.F. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc. Natl Acad. Sci. USA 1998, 95(20):11804-11809.
40. Schilling R., Ijaz S., Davidoff M., Lee J.Y., Locarnini S., Williams R., Naoumov N.V. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J. Virol. 2003, 77(16):8882-8892.
41. Sells M.A., Chen M.L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl Acad. Sci. USA 1987, 84(4):1005-1009.
42. Serruys B., Van Houtte F., Verbrugghe P., Leroux-Roels G., Vanlandschoot P. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 2009, 49(1):39-49.
43. Serruys B., Van Houtte F., Farhoudi-Moghadam A., Leroux-Roels G., Vanlandschoot P. Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. J. Gen. Virol. 2010, 91(Pt 3):643-652.
44. Stanfield R.L., Dooley H., Flajnik M.F., Wilson I.A. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 2004, 305(5691):1770-1773.
45. Stanfield R.L., Dooley H., Verdino P., Flajnik M.F., Wilson I.A. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J. Mol. Biol. 2007, 367(2):358-372.
46. Steven A.C., Conway J.F., Cheng N., Watts N.R., Belnap D.M., Harris A., Stahl S.J., Wingfield P.T. Structure, assembly, and antigenicity of hepatitis B virus capsid proteins. Adv. Virus Res. 2005, 64:125-164.
47. Streltsov V.A., Varghese J.N., Carmichael J.A., Irving R.A., Hudson P.J., Nuttall S.D. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc. Natl Acad. Sci. USA 2004, 101(34):12444-12449.
48. Streltsov V.A., Carmichael J.A., Nuttall S.D. Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci. 2005, 14(11):2901-2909.
49. Takahashi K., Machida A., Funatsu G., Nomura M., Usuda S., Aoyagi S., Tachibana K., Miyamoto H., Imai M., Nakamura T., Miyakawa Y., Mayumi M. Immunochemical structure of hepatitis B e antigen in the serum. J. Immunol. 1983, 130(6):2903-2907.
50. Thompson A.J., Nguyen T., Iser D., Ayres A., Jackson K., Littlejohn M., Slavin J., Bowden S., Gane E.J., Abbott W., Lau G.K., Lewin S.R., Visvanathan K., Desmond P.V., Locarnini S.A. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51(6):1933-1944.
51. Visvanathan K., Skinner N.A., Thompson A.J., Riordan S.M., Sozzi V., Edwards R., Rodgers S., Kurtovic J., Chang J., Lewin S., Desmond P., Locarnini S. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45(1):102-110.
52. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., Cauerhff A., Danquah W., Rissiek B., Scheuplein F., Schwarz N., Adriouch S., Boyer O., Seman M., Licea A., Serreze D.V., Goldbaum F.A., Haag F., Koch-Nolte F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 2009, 198(3):157-174.